Dafna Capital Management LLC Ngm Biopharmaceuticals Inc Transaction History

Dafna Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $411,693 - $577,809	-32,700 Reduced 30.38%	74,953 $980,000
Q1 2022 May 16, 2022	BUY	$13.81 - $18.6 $375,190 - $505,324	27,168 Added 33.76%	107,653 $1.64 Million
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $258,900 - $330,300	15,000 Added 22.91%	80,485 $1.43 Million
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $704,907 - $916,204	34,983 Added 114.69%	65,485 $1.38 Million
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $308,760 - $615,675	20,502 Added 205.02%	30,502 $601,000
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $249,899 - $319,300	10,000 New	10,000 $291,000
Q3 2019 Nov 14, 2019	SELL	$13.09 - $18.19 $82,008 - $113,960	-6,265 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$12.56 - $16.6 $78,688 - $103,999	6,265 New	6,265 $92,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.